-

05:09:47 AM

ORMP Stock News

ORMP - Oramed Pharmaceuticals, Inc

07/26/22 7:55 AM

Nasdaq : ORMP

clinical trial

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com), a

RHEA-AI

neutral

07/11/22 7:55 AM

Nasdaq : ORMP

conferences

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will present an in-person company overview and share the

RHEA-AI

neutral

07/07/22 7:55 AM

Nasdaq : ORMP

Oramed Letter to Shareholders

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage

RHEA-AI

very positive

06/01/22 7:55 AM

Nasdaq : ORMP

management

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board.Anne Peters, MD,

RHEA-AI

neutral

05/24/22 8:10 AM

Nasdaq : ORMP

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the

RHEA-AI

neutral

05/18/22 7:55 AM

Nasdaq : ORMP

conferences

Oramed to Present at H.C. Wainwright Global Investment Conference

Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person

RHEA-AI

neutral

05/03/22 8:10 AM

Nasdaq : ORMP

clinical trial

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP)

RHEA-AI

very positive

04/05/22 8:25 AM

Nasdaq : ORMP

Oramed Granted NASH Patent in Europe

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the European Patent Office has granted the Company the patent titled "Methods and

RHEA-AI

neutral

03/29/22 8:25 AM

Nasdaq : ORMP

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

NEW YORK, March 29, 2022 — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey commissioned by Oramed from

RHEA-AI

neutral

03/22/22 8:25 AM

Nasdaq : ORMP

conferences

Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that it will host a webinar with Key Opinion Leaders (KOLs) on the

RHEA-AI

neutral

1 2 3 4 5 6 Next

ORMP Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.oramed.com
CeoNadav Kidron
Security nameOramed Pharmaceuticals, Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees12
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1185 Avenue Of The Americas, 3Rd Floor
StateNew York
CityNew York
Zip10036
CountryUS
Phone16468441164

About Oramed Pharmaceuticals, Inc

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsulefor the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.